Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial.
about
Tamoxifen: catalyst for the change to targeted therapyProfile of V. Craig JordanCombination treatment of tamoxifen with risperidone in breast cancerFulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients.Is tamoxifen a genotoxic carcinogen in women?
P2860
Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Optimising endocrine approache ...... n and Raloxifene (STAR) trial.
@ast
Optimising endocrine approache ...... n and Raloxifene (STAR) trial.
@en
type
label
Optimising endocrine approache ...... n and Raloxifene (STAR) trial.
@ast
Optimising endocrine approache ...... n and Raloxifene (STAR) trial.
@en
prefLabel
Optimising endocrine approache ...... n and Raloxifene (STAR) trial.
@ast
Optimising endocrine approache ...... n and Raloxifene (STAR) trial.
@en
P1476
Optimising endocrine approache ...... n and Raloxifene (STAR) trial.
@en
P2093
V Craig Jordan
P304
P356
10.1016/J.EJCA.2006.09.012
P577
2006-10-24T00:00:00Z